SEC Tracker
Get the app

Lexeo Therapeutics LXEO

Lexeo Therapeutics FY 2023: net loss $66.4M; diluted EPS −$12.40

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.22
Material contract

Key figures from this report

These are the numbers Lexeo Therapeutics reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$66.4MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$12.40No year-earlier figure tagged10-K income statement, on EDGAR
  3. Cash and cash equivalents$121.5MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  4. Cash from operations−$59.5MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Lexeo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. SELLAS Life Sciences Group SLS public float $219M, Jun 30, 2025
  2. Precigen PGEN public float $219M, Jun 30, 2025
  3. Perspective Therapeutics CATX public float $213M, Jun 30, 2025
  4. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025
  5. Natures Sunshine Products NATR public float $211M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.